Interim Results of the Swiss Post Marketing Surveillance Monitoring Quality of Life and Treatment Satisfaction in Patients With Relapsing-Remitting Multiple Sclerosis
Latest Information Update: 19 Sep 2014
At a glance
- Drugs Fingolimod (Primary)
 - Indications Multiple sclerosis
 - Focus Therapeutic Use
 - Acronyms SWISSASCENT
 - Sponsors Novartis
 
Most Recent Events
- 19 Sep 2014 Status changed from not stated to recruiting.
 - 15 Sep 2014 New trial record